Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
AstraZeneca
US Department of Justice
Chinese Patent Office
Deloitte

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: RE43580

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE43580 protect, and when does it expire?

Patent RE43580 protects FORTICAL and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: RE43580
Title:Nasal calcitonin formulations
Abstract: .[.A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration..]. .Iadd.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof. .Iaddend.
Inventor(s): Stern; William (Tenafly, NJ)
Assignee: Unigene Laboratories, Inc. (Boonton, NJ)
Application Number:12/459,385
Patent Claim Types:
see list of patent claims
Composition; Use; Delivery;

Drugs Protected by US Patent RE43580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 DISCN No No ➤ Sign Up ➤ Sign Up Y NASAL ADMINISTRATION ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE43580

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3660401 ➤ Sign Up
Australia 783952 ➤ Sign Up
Canada 2399505 ➤ Sign Up
China 1183965 ➤ Sign Up
China 1422160 ➤ Sign Up
European Patent Office 1251867 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Chinese Patent Office
Harvard Business School
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.